Cardiovascular Longevity Protocol: CoQ10 + Omega-3 + Astaxanthin Stack

Key Takeaways

• This protocol combines four supplements with Level 1a or 1b RCT evidence in cardiovascular outcomes.
• CoQ10/Ubiquinol addresses mitochondrial bioenergetics — Q-SYMBIO showed 43% MACE reduction in heart failure.
• High-dose EPA Omega-3 addresses lipid biology and inflammation — REDUCE-IT showed 25% MACE reduction.
• Astaxanthin addresses oxidative stress and mitochondrial membranes — ITP showed 12% lifespan extension in mice.
• Nicotinamide Riboside addresses NAD+ availability — Martens trial showed BP and arterial stiffness improvement.
• This is an evidence-tiered protocol designed for adults 40+ seeking cardiovascular longevity, not a quick-fix for established disease.

Why a Cardiovascular Longevity Protocol?

Cardiovascular disease is the leading cause of mortality globally — accounting for approximately 17.9 million deaths annually. More importantly for longevity-focused individuals: cardiovascular dysfunction is one of the primary accelerants of biological aging. Vascular aging precedes and predicts:

• Cognitive decline (vascular contributions to dementia)
• Renal aging (kidney function depends on vascular health)
• Sarcopenia (muscle perfusion)
• Skin aging (vascular delivery to skin)
• Sexual dysfunction (vascular dependency)

Optimising cardiovascular function is therefore not just about preventing heart attacks — it's foundational to comprehensive healthspan extension.

This protocol is designed for adults 40+ with cardiovascular risk factors, family history, or longevity-focused supplementation goals. It is not a substitute for medical management of established cardiovascular disease, and individuals on cardiovascular medications should integrate this with physician oversight.

Coenzyme Q10 (Ubiquinol)

The Four-Compound Approach

The cardiovascular system requires multiple complementary forms of protection:

1. Mitochondrial energy — CoQ10 supports cardiomyocyte and vascular smooth muscle ATP production
2. Lipid biology — Omega-3 addresses triglycerides, inflammation, plaque stability
3. Oxidative stress — Astaxanthin provides exceptional mitochondrial membrane protection
4. NAD+ metabolism — NR addresses age-related vascular NAD+ decline

Each compound has independent RCT evidence in cardiovascular outcomes. The combination addresses different pathophysiological mechanisms — complementary rather than redundant.

Component 1: CoQ10/Ubiquinol

Dose: 100–200mg ubiquinol daily Timing: Morning with fatty meal Form: Kaneka Ubiquinol (patented form used in most positive trials)

Evidence base:

• Q-SYMBIO (2014): 43% reduction in MACE, 50% reduction in mortality in heart failure
• 2024 meta-analysis (11,372 patients): 5.6% absolute ejection fraction improvement
• 2025 statin myopathy review: Significant reduction in muscle pain and CK elevation

Mechanism: CoQ10 is essential for mitochondrial electron transport. Cardiomyocytes have the highest CoQ10 content of any tissue due to continuous ATP demand. Endogenous CoQ10 declines progressively with age — by 50% at age 80 vs peak. Statin therapy compounds this depletion by blocking the same HMG-CoA reductase pathway needed for CoQ10 biosynthesis.

Higher dose considerations:

• Heart failure (with physician): 300mg/day (Q-SYMBIO dose)
• Statin users with myopathy: 200mg/day
• Migraine prevention bonus: 300mg also reduces migraine frequency

Component 2: High-Dose Omega-3 (EPA-Predominant)

Dose: 2–4g combined EPA+DHA daily, with EPA emphasis for cardiovascular indications Timing: With fatty meal Form: Triglyceride form, IFOS-certified, refrigerated after opening

Evidence base:

• REDUCE-IT (NEJM, 2019): 4g/day icosapentaenoic acid (high-purity EPA) reduced MACE by 25% in 8,179 patients on statin therapy with elevated cardiovascular risk
• Multiple meta-analyses: Consistent triglyceride reduction (15–30%), modest BP reduction
• DHA-specific: Membrane composition, neuroprotection synergy

Mechanism: EPA is the precursor to anti-inflammatory eicosanoids (E-series resolvins, protectins) that resolve inflammation rather than amplifying it. EPA also competes with arachidonic acid for incorporation into phospholipid membranes, reducing pro-inflammatory eicosanoid production. DHA provides cardiac membrane fluidity and anti-arrhythmic effects.

Quality requirements:

• IFOS 5-star certification or equivalent third-party oxidation testing
• Triglyceride form (not ethyl ester) — ~70% better bioavailability
• Refrigerate after opening; use within 90 days
• EPA+DHA content verified

For specific cardiovascular indication, the REDUCE-IT protocol used 4g/day of high-purity EPA (icosapent ethyl, prescription as Vascepa). For general supplementation, 2g/day EPA+DHA balanced provides reasonable cost-benefit.

Omega-3 (EPA + DHA)

Component 3: Astaxanthin

Dose: 6–12mg daily Timing: With fatty meal (highly fat-soluble) Form: Natural Haematococcus pluvialis-derived, esterified

Evidence base:

• Harrison et al. (GeroScience, 2024): First natural compound to extend lifespan >10% in NIH ITP — 12% median male lifespan extension
• Multiple cardiovascular RCTs: Reduced oxidised LDL, improved endothelial function, modest BP reduction in hypertensive individuals
• Skin aging RCTs: Improved skin elasticity, reduced wrinkle depth at 6–12mg/day

Mechanism: Astaxanthin's molecular structure allows it to span mitochondrial membrane bilayers — uniquely positioning antioxidant activity at the site of ROS production. It activates the Nrf2 pathway, upregulating endogenous antioxidant enzymes (glutathione peroxidase, catalase, SOD) — a catalytic mechanism rather than direct antioxidant scavenging. Crosses both blood-brain and blood-retina barriers.

The 2024 ITP finding is particularly notable: this is the only natural compound to demonstrate >10% lifespan extension in this rigorous program in 20 years of testing.

Component 4: Nicotinamide Riboside

Dose: 300–500mg daily Timing: Morning Form: Niagen-licensed product preferred

Evidence base:

• Trammell et al. (Nature Communications, 2016): First PK study, dose-dependent NAD+ elevation
• Martens et al. (Nature Communications, 2018): 6 weeks at 1000mg/day reduced systolic BP ~9 mmHg in elevated-BP individuals; reduced arterial stiffness
• NCT03821623: Ongoing larger BP-focused trial

Mechanism: NR is phosphorylated by NRK1/NRK2 to produce NAD+, bypassing the rate-limiting NAMPT enzyme. Elevated NAD+ supports:

• Sirtuin activity (SIRT1-7) including vascular sirtuins (SIRT1)
• Mitochondrial energy metabolism
• DNA damage repair via PARP enzymes
• Vascular smooth muscle function — the basis for BP and arterial stiffness benefits

Why NR over NMN here: The cardiovascular evidence specifically rests on NR — Martens et al. directly tested NR for vascular outcomes. NMN has weaker cardiovascular-specific evidence.

Optional 5th Component: TMG

Dose: 500–1000mg daily Timing: With NR/NMN

For individuals taking sustained NR or NMN at 500mg+ daily, NAD+ flux can deplete methyl donors over time. TMG (trimethylglycine, betaine) provides methyl groups to replenish SAM-e and prevent methylation deficiency. At 300mg NR daily, this is rarely necessary; at 500mg+ chronic dosing, TMG co-supplementation is recommended.

Complete Dosing Schedule

Practical tip: All four primary compounds can be taken together with breakfast that contains some fat. This simplifies adherence — one supplement routine in the morning rather than multiple timing requirements.

Astaxanthin

Biomarkers to Track

Establish baseline before starting protocol:

Standard cardiovascular panel:

• Lipid panel (total, LDL, HDL, triglycerides)
• ApoB (better marker than LDL alone)
• hs-CRP (inflammation)
• HbA1c (metabolic)
• Blood pressure (multiple readings, ideally 24-hour)

Mitochondrial/longevity markers (where available):

• Plasma CoQ10 (some labs offer)
• Omega-3 Index (target >8%)
• GlycanAge or biological age markers

Recheck at 3 and 6 months:

• Lipid panel
• Blood pressure
• hs-CRP
• Subjective markers (energy, exercise capacity)

Expected Outcomes Timeline

Weeks 1–4: Subjective energy improvements (CoQ10 effect on cardiac/skeletal muscle) Weeks 4–8: Triglyceride reduction (Omega-3 effect) Weeks 6–12: Blood pressure reduction in elevated-BP individuals (NR + CoQ10 combined effect) Months 3–6: Skin and inflammation marker improvements (Astaxanthin systemic effects) Months 6+: Cumulative cardiovascular protection — effect on long-term events requires years of consistent use

Who Should Use This Protocol

Strong candidates:

• Adults 40+ with cardiovascular risk factors (elevated BP, LDL, family history)
• Individuals on statin therapy
• People with heart failure (with physician oversight)
• Anyone with elevated triglycerides or metabolic syndrome
• Longevity-focused individuals seeking comprehensive cardiovascular support

Less compelling for:

• Healthy adults under 40 without specific risk factors
• Individuals on warfarin without close monitoring (Omega-3 + warfarin requires INR monitoring)
• Active cancer treatment (CoQ10/NR effects on cancer biology debated)

What This Protocol Does NOT Replace

This is a supplementation protocol, not a substitute for:

• Statin therapy when indicated by cardiovascular risk
• Antihypertensive medication when blood pressure is elevated
• Lifestyle interventions — exercise, diet quality, sleep, stress management
• Smoking cessation — the single highest-yield cardiovascular intervention

The supplements complement standard cardiovascular medicine; they do not replace it. Patients should not modify prescription medications based on supplement protocols without physician consultation.

Cost Analysis

Annual cost estimates (US prices, 2026):

Compare to:

• Statin generic: $50–$200/year (covered by insurance for most)
• ACE inhibitor: $50–$300/year

Supplementation costs should be considered alongside, not as replacement for, evidence-based cardiovascular pharmaceuticals.

Drug Interactions to Monitor

Anticoagulants (warfarin):

• Omega-3 may potentiate effect at high doses (>3g/day)
• CoQ10 may reduce warfarin efficacy
• Monitor INR closely with any supplement changes

Antihypertensives:

• All four supplements may modestly lower BP
• Cumulative hypotensive effect possible
• Monitor BP, may need dose adjustments

Statins:

• CoQ10 supplementation is specifically beneficial
• Check liver enzymes if doses are high

Diabetes medications:

• NR may modestly improve insulin sensitivity
• Monitor glucose

Frequently Asked Questions

How much does this cardiovascular protocol cost per year?

Annual cost ranges from $750-$1,750 depending on brand quality: CoQ10 Ubiquinol 100mg ($200-400), Omega-3 2g EPA+DHA ($150-400), Astaxanthin 12mg ($100-250), and NR 300mg Niagen ($300-700). This is in addition to, not a replacement for, any prescribed cardiovascular medications.

Can I take all four supplements together?

Yes — all four compounds can be taken together with a breakfast containing some fat. CoQ10, Omega-3, and Astaxanthin are all fat-soluble and benefit from the same fatty meal. NR can be taken with or without food. One morning routine simplifies adherence.

Is this protocol safe with blood pressure medication?

All four supplements may modestly lower blood pressure. The cumulative hypotensive effect is possible, so monitor BP and discuss with your physician. Dose adjustments to antihypertensive medications may be needed. This protocol complements, not replaces, prescribed therapy.

How long before I see results from this stack?

Subjective energy improvements from CoQ10 typically appear in weeks 1-4. Triglyceride reduction from Omega-3 shows at weeks 4-8. Blood pressure effects from NR and CoQ10 emerge at weeks 6-12. Skin and inflammation improvements from Astaxanthin at months 3-6. Long-term cardiovascular protection requires years of consistent use.

Should I take CoQ10 as ubiquinone or ubiquinol?

Under 40: either form works. Over 40: ubiquinol is preferred (3-4x better bioavailability). Over 60: ubiquinol strongly preferred (6-8x better bioavailability). Look for Kaneka Ubiquinol — the patented form used in most positive clinical trials. Take with a fatty meal for optimal absorption.

Related Research

• The 2024 Q-SYMBIO Follow-Up: 10 Years of CoQ10 Cardiovascular Data
• NMN vs NR: Which NAD+ Precursor Actually Works in 2026?
• Astaxanthin: The First Natural Supplement With 10%+ Lifespan Extension Evidence

Scientific References

1. Mortensen SA, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO. JACC Heart Failure (2014). PMID 25282031

2. Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). NEJM (2019). PMID 30415628

3. Harrison DE, et al. Astaxanthin and meclizine extend lifespan in UM-HET3 male mice. GeroScience (2024). PMID 38041783

4. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications (2018). PMID 29599478

5. Borges JYV. The Role of Coenzyme Q10 in Cardiovascular Disease Treatment: 2024 Systematic Review and Meta-Analysis. medRxiv (2024). DOI